Nifedipine Tablet, Extended Release
Product Images NDC 68788-7642
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Nifedipine (NDC 68788-7642). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
02 (Image 02)
The given text mentions the adverse effects of Nifedipine extended-release tablets including headache, fatigue, dizziness, constipation, and nausea along with the percentage of occurrence among 707 patients. It also provides the corresponding percentage of patients experiencing similar effects in the placebo group consisting of 266 individuals.*
03 (Image 03)
This is a table comparing the percentage of adverse effects experienced by patients taking Nifedipine capsules versus a placebo. The adverse effects stated include dizziness, lightheadedness, giddiness, flushing, heat sensation, headache, weakness, nausea, heartburn, muscle cramps, tremors, peripheral edema, nervousness, mood changes, palpitations, dyspnea, cough, wheezing, nasal congestion, and sore throat. The sample size of patients is given for both Nifedipine and placebo groups.*
04 (Image 04)
Nifedipine Extended Release Tablet Usp 30mg (Image 05)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.